Victory Capital Management Inc Sage Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$40.65 - $59.54 $720,846 - $1.06 Million	17,733 Added 72.59%	42,161 $1.98 Million
Q1 2023 May 02, 2023	BUY	$37.27 - $46.57 $349,555 - $436,780	9,379 Added 62.32%	24,428 $1.02 Million
Q4 2022 Feb 10, 2023	BUY	$32.2 - $43.61 $1,706 - $2,311	53 Added 0.35%	15,049 $573,000
Q4 2022 Feb 09, 2023	SELL	$32.2 - $43.61 $406,879 - $551,055	-12,636 Reduced 45.73%	14,996 $571,000
Q3 2022 Nov 02, 2022	BUY	$32.28 - $43.27 $691,017 - $926,280	21,407 Added 343.89%	27,632 $1.08 Million
Q2 2022 Aug 01, 2022	BUY	$27.52 - $37.99 $171,312 - $236,487	6,225 New	6,225 $201,000
Q1 2022 May 04, 2022	SELL	$30.71 - $45.71 $335,598 - $499,518	-10,928 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$37.06 - $47.11 $62,371 - $79,286	1,683 Added 18.2%	10,928 $465,000
Q3 2021 Nov 02, 2021	BUY	$40.26 - $57.37 $97,670 - $139,179	2,426 Added 35.58%	9,245 $410,000
Q2 2021 Aug 03, 2021	SELL	$54.88 - $79.29 $37.4 Million - $54.1 Million	-682,185 Reduced 99.01%	6,819 $387,000
Q1 2021 May 04, 2021	SELL	$70.65 - $96.76 $3.17 Million - $4.34 Million	-44,893 Reduced 6.12%	689,004 $51.6 Million
Q4 2020 Feb 01, 2021	SELL	$58.41 - $89.06 $20 Million - $30.5 Million	-342,840 Reduced 31.84%	733,897 $63.5 Million
Q3 2020 Nov 09, 2020	BUY	$41.13 - $62.45 $3.93 Million - $5.97 Million	95,631 Added 9.75%	1,076,737 $65.8 Million
Q2 2020 Aug 07, 2020	SELL	$25.95 - $43.15 $2.99 Million - $4.97 Million	-115,252 Reduced 10.51%	981,106 $40.8 Million
Q1 2020 May 04, 2020	BUY	$26.15 - $77.24 $8.41 Million - $24.9 Million	321,771 Added 41.54%	1,096,358 $31.5 Million
Q4 2019 Feb 06, 2020	SELL	$60.18 - $154.77 $17.4 Million - $44.8 Million	-289,595 Reduced 27.21%	774,587 $55.9 Million
Q4 2019 Feb 04, 2020	BUY	$60.18 - $154.77 $29 Million - $74.5 Million	481,324 Added 82.58%	1,064,182 $70.5 Million
Q3 2019 Nov 12, 2019	BUY	$140.29 - $189.96 $14.9 Million - $20.1 Million	105,967 Added 22.22%	582,858 $81.8 Million
Q2 2019 Aug 15, 2019	BUY	$157.85 - $183.09 $6.74 Million - $7.81 Million	42,670 Added 9.83%	476,891 $87.3 Million
Q1 2019 May 03, 2019	SELL	$89.33 - $163.65 $2.62 Million - $4.8 Million	-29,320 Reduced 6.33%	434,221 $69.1 Million
Q4 2018 Feb 05, 2019	BUY	$81.94 - $139.71 $3.51 Million - $5.98 Million	42,806 Added 10.17%	463,541 $44.4 Million
Q3 2018 Nov 01, 2018	SELL	$138.11 - $169.04 $7.59 Million - $9.29 Million	-54,930 Reduced 11.55%	420,735 $59.4 Million
Q2 2018 Aug 02, 2018	BUY	$140.36 - $175.76 $5.73 Million - $7.18 Million	40,850 Added 9.39%	475,665 $74.5 Million
Q1 2018 May 04, 2018	BUY	$152.15 - $192.33 $23.3 Million - $29.4 Million	152,885 Added 54.23%	434,815 $70 Million
Q4 2017 Feb 01, 2018	SELL	$60.72 - $167.34 $3 Million - $8.28 Million	-49,475 Reduced 14.93%	281,930 $46.4 Million
Q3 2017 Oct 27, 2017	SELL	$61.4 - $88.52 $7 Million - $10.1 Million	-114,080 Reduced 25.61%	331,405 $20.6 Million
Q2 2017 Aug 07, 2017	BUY	N/A	445,485	445,485 $35.5 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account